BofA/Merrill Lynch Downgrades Gilead Sciences (GILD) to Underperform

Jefferies Says Too Early to Judge the Impact of AbbVi Competition on Gilead (GILD)

Jefferies analyst Thomas Wei reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) while bumping his price target to $84.00 (from $82.00) following news yesterday that Express Scripts (NASDAQ: ESRX) said they will only cover AbbVie (NYSE:... More

Investors Should Have More Faith in Gilead Sciences (GILD), Maxim Group Says

Maxim Group analyst Jason Kolbert weighed in on Gilead Sciences (NASDAQ: GILD) after Express Scripts (NASDAQ: ESRX) announced that Abbvie's (NYSE: ABBV) Viekira will be the exclusive option for genotype 1 Hepatitis C patients.

Amid the sell-off, Kolbert said investors should have faith in the company as... More

Gilead Sciences (GILD) Sell-Off is an Overreaction, Baird Said; Doesn't See All Out Price War

Baird analyst Brian Skorney was the latest to weigh in on Gilead Sciences (NASDAQ: GILD) after Abbvie (NYSE: ABBV) and Express Scripts (NASDAQ: ESRX) reached an agreement to put Viekira on the national formulary for Hep C and drop Gilead

"Although not unexpected, we do see this... More

Gilead (GILD) Sell-Off Seen as Opportunity at Wells Fargo

Wells Fargo called today's sell-off in Gilead Sciences (NASDAQ: GILD) an opportunity. The decline follows news Express Scripts (NASDAQ: ESRX) selected AbbVie's (NYSE: ABBV) Viekira Pak as its exclusive treatment... More

Buy Gilead Sciences (GILD) on Weakness, BMO Capital Says; PT Dropped $20 on News

BMO Capital analyst Jim Birchenough dropped his price target on Gilead Sciences (NASDAQ: GILD) to $150.00 (from $170.00) after assessing the impact of Express Scripts' (NASDAQ: ESRX) move make GILD competitor AbbVie's (NYSE: ABBV) VIEKIRA... More

Express Scripts/AbbVie Deal a 'Double Whammy' for Gilead Sciences (GILD); Deal Could Have Sector Wide Repercussions

JPMorgan analyst Cory Kasimov weighed in on Gilead Sciences (NASDAQ: GILD), which is down 13.7% after Express Scripts (NASDAQ: ESRX) announced a exclusive multi-year agreement with AbbVie (NYSE: ABBV) to make Viekira Pak the exclusive option for GT1 patients covered by its National Preferred... More

Deutsche Bank Comments on Gilead (GILD); CVS Health (CVS) Could Be Next to Decide on Formulary

Deutsche Bank analyst Robyn Karnauskas commented on Gilead Sciences (NASDAQ: GILD) in a research note Monday. The stock dropped 11% after Express Scripts (NASDAQ: ESRX) said AbbVie's (NYSE: ABBV) Viekira Pak will be the exclusive option for genotype 1 Hepatitis C patients covered by the express scripts national preferred formulary.

"ESRX covers 85-90M lives in the US and this decision applies to 25M lives which are covered under commercial program. ESRX noted that... More

Pre-Open Stock Movers 12/22: (CZR) (CACQ) (ACHN) Higher; (GILD) (OCN) (NQ) Lower (more...)

Caesars Entertainment (NASDAQ: CZR) 14.6% HIGHER; Caesars Entertainment and Caesars Acquisition Company (NASDAQ: CACQ) today announced that they have entered into a definitive agreement to merge in an all-stock transaction. The merged company will be one of the largest gaming and entertainment companies in the world. Upon completion of the merger and the proposed restructuring of Caesars Entertainment Operating Company, Inc. ("CEOC"), the merged company will be well capitalized and positioned for sustainable long-term growth and value creation. Upon the completion of the transaction, Caesars... More

Baird Remains Cautious on Enanta (ENTA) Despite Viekira Approval (GILD) (ABBV)

Baird analyst Brian Skorney remains cautious on Enanta Pharmaceuticals (NASDAQ: ENTA) despite FDA approval for Hep C combo Viekira.

"Viekira's approval sets up one of the more closely watched competitive dynamics in the sector. As expected, the regimen's label is more... More

AbbVie's (ABBV) VIEKIRA PAK Seen as Limited Threat to Gilead's (GILD) HCV Dominance, BMO Capital Says

BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $170 price target on Gilead Sciences (NASDAQ: GILD) after AbbVie (NYSE: ABBV) received FDA approval for VIEKIRA PAK. The analyst views VIEKIRA label as too restrictive, making it a limited threat to Gilead in HCV.

On VIEKIRA PAK label, Birchenough notes:... More

Gilead (GILD) Tanks; Analyst Comments on Express Scripts (ESRX) Viekira Pak Announcement (ABBV)

Shares of Gilead Sciences (NASDAQ: GILD) declined premarket Monday after Express Scripts (NASDAQ: ESRX) said AbbVie's (NYSE: ABBV) Viekira Pak will be the exclusive option for genotype 1 Hepatitis C patients covered by the express scripts national preferred formulary.

Commenting on developments,... More

AbbVie (ABBV): Express Scripts (ESRX) Says Viekira Pak Will Be the Exclusive Option for Genotype 1 Hepatitis C Patients (GILD)

Offering an unprecedented solution to an unprecedented healthcare challenge, Express Scripts (NASDAQ: ESRX) today announced an update to its National Preferred Formulary that will significantly expand access to AbbVie's (NYSE: ABBV) new medication, Viekira Pak®,a breakthrough treatment for hepatitis C.

Viekira Pak, approved by the U.S. Food and Drug Administration on December 19, was determined to be at least clinically equivalent to Harvoni® (ledipasvir and sofosbuvir) and Sovaldi® (sofosbuvir) by Express Scripts' independent Pharmacy & Therapeutics Committee. As a result of the committee's determination, Viekira Pak... More

Express Scripts (ESRX), AbbVie (ABBV) Enter Agreement for Recently-Approved Viekira Pak

Express Scripts (Nasdaq: ESRX) announced an update to its National Preferred Formulary that will significantly expand access to AbbVie's (NYSE: ABBV) new medication, Viekira Pak®, a breakthrough treatment for hepatitis C.

Viekira Pak, approved by the U.S. Food and Drug Administration on December 19, was determined to be at least clinically equivalent to Gilead's (Nasdaq: GILD) Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir) by Express Scripts' independent Pharmacy & Therapeutics Committee. As a result of the committee's determination, Viekira Pak will... More